Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
TNFRSF6B Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 6B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF6B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FCGR3B Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor III-B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL9 Biologics Sequence Review Report 2026: Interleukin-9 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
IL1R1 Biologics Sequence Review Report 2026: Interleukin-1 receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of IL1R1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF5 Biologics Sequence Review Report 2026: Fibroblast growth factor 5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF3 Biologics Sequence Review Report 2026: Fibroblast growth factor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FGF6 Biologics Sequence Review Report 2026: Fibroblast growth factor 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGAV Biologics Sequence Review Report 2026: Integrin alpha-V Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGAV protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD2 Biologics Sequence Review Report 2026: T-cell surface antigen CD2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD1A Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD1a Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD1A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGB1 Biologics Sequence Review Report 2026: Integrin beta-1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ITGB2 Biologics Sequence Review Report 2026: Integrin beta-2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ITGB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
194
195
196
197
198
>>
1503
>